|
Albertus Dominicus Marcellinus Erasmus Osterhaus, PhD (born 2 June 1948), known as Ab Osterhaus, is a leading Dutch virologist and influenza expert. A Professor of Virology at Erasmus University Rotterdam since 1993, Osterhaus is known throughout the world for his work on SARS and H5N1, the pathogen that causes avian influenza. As the country's foremost virus expert, he frequently appears on Dutch television. He has been criticised for exaggerating the consequences of the 2009 flu pandemic and pushing for extensive measures, even though the pandemic influenza (H1N1) is now treated as if it were a common flu. In September 2009, a controversy arose when it became known Osterhaus has a 9.8% share in ViroClinics B.V, a pharmaceutical company that supposedly benefits from the 34 million vaccines Health minister Ab Klink bought based on his advice as government consultant. Osterhaus maintains he did nothing against the law and that he does not personally benefit from the order. ==Life== Osterhaus was born into a Roman Catholic family of seven and grew up in Slotermeer, Amsterdam. From 1967 onwards he studied veterinary medicine at Utrecht University and graduated ''cum laude'' in 1974. He received his PhD degree in 1978 at the same university for a dissertation entitled "Feline infectious peritonitis: identification, propagation and epidemiology". He fulfilled several positions in his 16-year career at the Netherlands National Institute for Public Health and the Environment (RIVM) in Bilthoven, the last of which was head of the laboratory for Immunobiology. During that period he was also a part-time Professor of Environmental Virology at the Institute for Virology in Utrecht, a position he still holds as of 2009. In 1993 he became Professor of Virology at the Medical Faculty of Erasmus University and also head of the Department of Virology at Erasmus University Medical Centre Rotterdam. Osterhaus played an important role in the identification of the SARS coronavirus. In February 2004, his team found that ''Pegylated interferon alpha'', a drug used for the treatment of patients with Hepatitis C, helps combat the virus that causes SARS. The results were published in ''Nature'' in March 2004. On 2 January 2008 an article appeared in ''PLoS ONE'' describing a new vaccine for H5N1 virus, developed by Rotterdam pharmaceutical company ViroClinics B.V., a spin-out company of the Erasmus MC where Osterhaus works as scientific advisor. Professor Osterhaus holds various editorial positions for scientific journals, holds several patents, has been supervisor of more than 35 PhD students and has identified more than a dozen “new” viral pathogens〔(【引用サイトリンク】publisher=ESWI )〕 and he is author of more than 700 scientific papers, including more than fifty in world-class international journals like ''Nature'', ''Science'' and ''The Lancet''. Dr Osterhaus served as member and chairman of many international scientific committees, most notably four WHO reference centres, the Dutch Influenza Centre, the Dutch Health Council and the European Scientific Working group on Influenza (ESWI). He is also a member of Royal Netherlands Academy of Arts and Sciences (KNAW) since 2001. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ab Osterhaus」の詳細全文を読む スポンサード リンク
|